Genmab — December 2023

[E_L]

"This real world analysis is important since 80% of these pts wouldn’t have been eligible for the MagesTEC-1 trial" https://twitter.com/Curley_MD/status/1733548449336107277

[Klarussen]

@E L: can you perhaps explain for us novices in plain terms what it means forwardlooking, please?

[E_L]

Smoldering multiple myeloma is an early form of multiple myeloma that isn't cancer yet, which usually progresses to active myeloma, but at a slow rate. The jury is still out wether or not you should treat this already at this stage, or wait and see if it actually becomes MM and treat it then.

[E_L]

JNJ's Centaurus trial is one of the trials trying to state that you should start treating early with Daratumumab

[E_L]

Trials in general exclude a lot of patients based on criteria set by the investigator. This COULD give better results if patient selection is biased. The real world analysis for Teclistamab is of interest as these are patients treated in the real world outside of those trials, so without those stringent exclusion criteria where some patients are not allowed to participate.

[E_L]

And it shows that results are very similar to the trial, so that is good news as these results were very good

[Klarussen]

Thank you. This makes a lot of sense. Early intervention is better than later trying to cure

[E_L]

well, don't forget that there are also side effects of treatment AND that these treatments are very expensive, so you don't want to give them if you do not have a high degree of confidence that they actually help

[E_L]

unless you are JNJ, then you always want to sell them

[Klarussen]

Well my biggest concern with J&J is that, depending on the arbitrary case, they do not want to take CD38 further because there`s more profit and money invested in Darzalex for the time being, but thats another matter...

[Klarussen]

And we do not know a lot about CD38s potential at this point anyway, so... pure speculation of course

[E_L]

there will be plentiful potential in hexabody-CD38 if the data are as we are hoping for , even if JNJ will not opt in, there is possibly a lot of value in that drug for Genmab. But a JNJ opt in would make life a lot easier...

[Klarussen]

Exactly, life would be a lot easier and things would progress much much quicker. And what if J&J opts in and then choses to slow down things until the patent of Darzalex runs out?

[Bulder]

En ting jeg aldrig rigtig har forstået: Hvis jnj vælger ikke at opte in, har Genmab forpligtet sig til ikke at udvikle hex38 i MM og Amy, hvor Dara er godkendt. Hvis Genmab taber voldgiftsappellen, kunne jnj fristes til ikke at opte in, fordi der venter en royaltyfri årrække. Og så står Genmab for alvor med håret i postkassen. Jeg begriber ikke, at Genmab er gået med på de betingelser, men det kan nogen måske forklare?

[Bulder]

… årrække på dara.

[JKY_VH]

Nej, den slags er tåbeligt og helt uden formål at gå med til den slags betingelser. Har ferieafløseren været på spil? Bortset fra det, er jeg sikker på at JNJ nok skal opte in.

[E_L]

was this not part of the original daratumumab agreement that Genmab can not develop a competitive antibody? can't remember for sure...

[E_L]

@Klaussen old dara agreement stipulates how "Janssen shall use Commercially Reasonable Efforts to Develop, Manufacture and Commercialise Licensed Product" - you can assume this to be the same for HexaCD38 https://www.sec.gov/Archives/edgar/data/1434265/000104746919003334/a2238822zex-10_1.htm

[Bulder]

No if they opt in they’ll not slow down. But they are free not to opt in, even if hex38 is a good drug.

[JKY_VH]

Det må koste på CSR-kontoen, hvis man spænder ben for færdigudviklingen af et præparat der er markant bedre end Dara. Jeg tror de skyder sig selv i foden, hvis de gør det, og forhåbentlig bliver de overhalet indenom af konkurrenterne. Så nej, det forestiller jeg mig ikke vil ske.